Home › Research › Down syndrome and Alzheimer's
Dementia in Down syndrome: unique insights for Alzheimer disease research
Lott IT, Head E.. Nature reviews. Neurology, 2019-03-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Virtually all adults with Down syndrome (DS) show the neuropathological changes of Alzheimer disease (AD) by the age of 40 years. This association is partially due to overexpression of amyloid precursor protein, encoded by APP, as a result of the location of this gene on chromosome 21. Amyloid-β accumulates in the brain across the lifespan of people with DS, which provides a unique opportunity to understand the temporal progression of AD and the epigenetic factors that contribute to the age of dementia onset. This age dependency in the development of AD in DS can inform research into the presentation of AD in the general population, in whom a longitudinal perspective of the disease is not often available. Comparison of the risk profiles, biomarker profiles and genetic profiles of adults with DS with those of individuals with AD in the general population can help to determine common and distinct pathways as well as mechanisms underlying increased risk of dementia. This Review evaluates the similarities and differences between the pathological cascades and genetics underpinning DS and AD with the aim of providing a platform for common exploration of these disorders.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. This review states that "virtually all adults with Down syndrome" show the brain changes of Alzheimer's disease by age 40, partly because the APP gene, which makes the amyloid precursor protein, sits on chromosome 21 and is overexpressed. It summarises earlier research rather than reporting new data, and the age of 40 refers to brain changes, not to when dementia symptoms begin; it does not report a treatment.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lott, I. T., & Head, E. (2019). Dementia in Down syndrome: unique insights for Alzheimer disease research. Nature reviews. Neurology. https://doi.org/10.1038/s41582-018-0132-6
Vancouver
Lott IT, Head E. Dementia in Down syndrome: unique insights for Alzheimer disease research. Nature reviews. Neurology. 2019. doi:10.1038/s41582-018-0132-6. PMID: 30733618.
BibTeX
@article{lott2019-30733618,
author = {Lott, I. T. and Head, E.},
title = {{Dementia in Down syndrome: unique insights for Alzheimer disease research}},
journal = {Nature reviews. Neurology},
year = {2019},
doi = {10.1038/s41582-018-0132-6},
pmid = {30733618},
url = {https://doi.org/10.1038/s41582-018-0132-6}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- This association is partially due to overexpression of amyloid precursor protein, encoded by APP, as a result of the location of this gene on chromosome 21.
- Comparison of the risk profiles, biomarker profiles and genetic profiles of adults with DS with those of individuals with AD in the general population can help to determine common and distinct pathways as well as mechanisms underlying increased risk of dementia.
Why it matters
This review states that "virtually all adults with Down syndrome" show the brain changes of Alzheimer's disease by age 40, partly because the APP gene, which makes the amyloid precursor protein, sits on chromosome 21 and is overexpressed. The authors argue that this predictable timing lets researchers study how Alzheimer's develops over a lifetime, and that comparing the risk, biomarker and genetic profiles of adults with Down syndrome with those of people who have Alzheimer's in the general population can show which disease pathways are shared and which differ. It summarises earlier research rather than reporting new data, and the age of 40 refers to brain changes, not to when dementia symptoms begin; it does not report a treatment.
Study details
- Study designlongitudinal study
- Evidence strengthModerate
How this study scored 60/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Nature reviews. Neurology) |
| Journal's citation record | 3 / 4 | Nature Reviews Neurology: journal h-index 269 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 385 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 42.8 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 4 / 6 | Cited 10.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 37 other studies in this library |
| Still being cited | 3 / 4 | Cited 151 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Elizabeth Head: h-index 98 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of California, Irvine: institution h-index 1,195 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30733618) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 54.
Later studies that cite this one
37 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.